FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Regulatory Review Period Corrected for Enspryng

Federal Register notice: FDA corrects a 7/13/2022 notice that announced the regulatory review period determination for Genentechs Enspryng (satralizum...

latest-news-card-1
Human Drugs

Ex-FDAer Schiller on Accelerated Approval Guide

Aetion chief legal/regulatory officer and former FDA associate commissioner for policy Lowell Schiller says the agency should address the use of exter...

Medical Devices

Melanoma Imaging Device Get Breakthrough Status

FDA grants Orlucent a breakthrough device designation for the companys Orlucent Skin Fluorescence Imaging System.

latest-news-card-1
Human Drugs

Lawyers Motion to Remain Anonymous Granted

In an unprecedented decision, the DC District Court temporarily grants an attorneys motion to keep his identity secret in connection with a form FDA-4...

latest-news-card-1
Human Drugs

FDA OKs New Opioid Use Disorder Option

FDA approves a Braeburn Inc. NDA for Brixadi (buprenorphine) extended-release injection (subcutaneous) for treating moderate to severe opioid use diso...

latest-news-card-1
Medical Devices

Abbott Touts Data on Dual Chamber Pacemaker

Abbott reports new data from an IDE study of its AVEIR dual-chamber i2i leadless pacemaker, described as the worlds first.

latest-news-card-1

FDA Approval Reciprocity Bill Reintroduced

Rep. Chip Roy (R-TX) reintroduces the Reciprocity Ensures Streamlined Use of Lifesaving Treatments" (RESULT) Act that would expedite FDAs approval pro...

latest-news-card-1
Human Drugs

FDA Approves New Treatment for Pneumonia

FDA approves an Entasis Therapeutics NDA for Xacduro (sulbactam and durlobactam for injection), a new treatment for hospital-acquired bacterial pneumo...

latest-news-card-1
Human Drugs

Rain Oncology Scraps Milademetan

Rain Oncology says it will cease further development of milademetan in dedifferentiated liposarcoma after reporting disappointing topline data from a ...

latest-news-card-1
Federal Register

FDA Withdraws NDA on Abbotts Cyclert

Federal Register notice: FDA withdraws approval of Abbotts NDA for Cyclert (pemoline) tablets, indicated for treating attention-deficit/hyperactivity ...